Copaltra
Food supplement declared in France, declaration No 2024-1-1537, decision dated 30 January 2024
Copaltra (IPHYM) is a food supplement declared in France. Status: declared in France, may be marketed. None of the rules we check flags an issue with its declared composition.
- Brand
- IPHYM
- Food business operator placing the product on the market
- Laboratoires IPHYM
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Capsule
- Daily dose
- 4 gélules par jour
- Directions for use
- 2 gélules ¼ d’heure avant les repas du midi et du soir
- Intended populations
- People over 60, Men, Women
- Not recommended (according to the manufacturer)
- Adolescents (under 18), Breastfeeding women, Pregnant women, Kidney disease, Heart problems
- Objectives stated by the manufacturer (these are not authorised claims)
- Slimming / Blood sugar
Declaration 138664, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Olea europaea subsp. europaea | Feuille | Extrait sec alcoolique | 720 mg |
| Vaccinium myrtillus L. | Feuille | Poudre (de plantes séchées ou broyées) | 400 mg |
Additives
Hydroxypropyl Méthyl Cellulose
Other ingredients
maltodextrine
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Label warnings
Produit destiné à l'adulte. Déconseillé chez l’enfant et l’adolescent, la femme enceinte et allaitante et en cas d’insuffisance cardiaque ou rénale. Ne pas dépasser la dose journalière recommandée. Ne se substitue pas à un régime alimentaire varié et sera utilisé dans le cadre d’un mode de vie sain. Ne pas laisser à la portée des jeunes enfants.
Regulatory points
None of the rules we check applies to the declared ingredients.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Olea europaea subsp. europaea
Read the warning, when it applies and the studies cited
OLIVE LEAF - OLEA EUROPAEA
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you pregnant or breastfeeding (EMA 2017).
Sources cited by Health Canada (1)
- EMA 2017: European Medicines Agency. European Union herbal monograph on Olea europaea L., folium. [Accessed 2024 November 27]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-olea-europaea-l-folium-first-version_en.pdf
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a kidney disorder (EMA 2017).
Sources cited by Health Canada (1)
- EMA 2017: European Medicines Agency. European Union herbal monograph on Olea europaea L., folium. [Accessed 2024 November 27]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-olea-europaea-l-folium-first-version_en.pdf
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking other diuretics (EMA 2017).
Sources cited by Health Canada (1)
- EMA 2017: European Medicines Agency. European Union herbal monograph on Olea europaea L., folium. [Accessed 2024 November 27]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-olea-europaea-l-folium-first-version_en.pdf
Known adverse reactions
Condition of application: All products except those making a diuretic claim.
When using this product diuretic effect may occur.
- Vaccinium myrtillus L.
Read the warning, when it applies and the studies cited
BILBERRY - VACCINIUM MYRTILLUS - Buccal
Route of administration: Buccal (Blumenthal et al. 2000)
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 30 January 2026
BILBERRY - VACCINIUM MYRTILLUS - Oral
Route of administration: Oral (Blumenthal et al. 2000)
Cautions and warnings
Condition of application: Relief of diarrhea.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: Slowing the progression of disorders of the eye and to relieve symptoms related to non-complicated CVI.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Other declarations with the same name
In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.
- Copaltra IPHYM, declared in 2022, earlier declaration, replaced by the 2024 declaration : different composition: 1 ingredient(s) added, 1 missing
Brand : IPHYM
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.